A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Bristol-Myers Squibb
Novartis
Kivu Bioscience Inc.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Genentech, Inc.
AstraZeneca
Boehringer Ingelheim
Fox Chase Cancer Center
AbbVie
Eli Lilly and Company
National Cancer Institute (NCI)
Johnson & Johnson Enterprise Innovation Inc.
Royal Marsden NHS Foundation Trust
The Methodist Hospital Research Institute
OncoC4, Inc.
Exscientia AI Limited
Seagen Inc.
Seagen Inc.
KaliVir Immunotherapeutics
Pfizer
Pfizer
Fate Therapeutics
AstraZeneca
Zumutor Biologics Inc.
H. Lee Moffitt Cancer Center and Research Institute
Pfizer
Arcus Biosciences, Inc.
University of Chicago
IDEAYA Biosciences
Memorial Sloan Kettering Cancer Center
Sotio Biotech Inc.
Dana-Farber Cancer Institute
Erasca, Inc.
EMD Serono
EpiBiologics
Eli Lilly and Company
GlaxoSmithKline
Bayer
Coherus Oncology, Inc.
Mayo Clinic
Stanford University
University of Colorado, Denver
Merck Sharp & Dohme LLC
Exelixis
University of California, Davis
Vanderbilt-Ingram Cancer Center
Vanderbilt-Ingram Cancer Center
University of Chicago
Emory University